The ultrasound business of GE Medical Systems was singled outfor praise last week in GE's announcement of fiscal 1996 financialresults. The Fairfield, CT, conglomerate said that new productsdrove the ultrasound business to grow 25% in a relatively
The ultrasound business of GE Medical Systems was singled outfor praise last week in GE's announcement of fiscal 1996 financialresults. The Fairfield, CT, conglomerate said that new productsdrove the ultrasound business to grow 25% in a relatively flatoverall market.
GEMS's ultrasound unit last year introduced major upgradesfor its Logiq line of scanners, and former GEMS president andCEO John Trani said last month that the upgrades were the keyto a successful year for the business (SCAN 1/8/97). Overall,GEMS was one of five GE businesses that reported double-digitincreases in operating profit.
For the year, GE reported record revenues of $79.2 billion,up 13% compared with $70 billion in 1995. Earnings also set arecord, with the company posting net income of $7.3 billion, up11% compared with $6.6 billion in 1995. The results may make GEthe most profitable company in the U.S. for the year.
GE did not break out sales and earnings figures for GE MedicalSystems, other than to report on the growth in ultrasound andoperating profit. GEMS in the past has reported sales of over$3.5 billion.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.